SPC-CEFPROZIL DIN 02293579
Status: Marketed
Holder: SUN PHARMA CANADA INC
Molecule: CEFPROZIL (CEFPROZIL MONOHYDRATE)
Available to quote
Health Canada record
| Active ingredient(s) | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG |
|---|---|
| Dosage form | Powder For Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01DC10 CEFPROZIL |
| Original market date | 17-Apr-2007 |
| Current status date | 31-Oct-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sun Pharma Canada Inc. — licence 3-002572, currently licensed, last inspection rating C (2026-06-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEFPROZIL (CEFPROZIL MONOHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02347261 | AURO-CEFPROZIL | AURO PHARMA INC | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG | Marketed |
| 02347288 | AURO-CEFPROZIL | AURO PHARMA INC | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Marketed |
| 02329204 | SPC-CEFPROZIL | SUN PHARMA CANADA INC | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG | Marketed |
| 02293536 | SPC-CEFPROZIL | SUN PHARMA CANADA INC | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG | Marketed |
| 02293528 | SPC-CEFPROZIL | SUN PHARMA CANADA INC | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Marketed |
| 02292998 | APO-CEFPROZIL | APOTEX INC | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Dormant |
| 02293005 | APO-CEFPROZIL | APOTEX INC | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG | Dormant |
| 02362872 | AVA-CEFPROZIL | AVANSTRA INC | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Cancelled Post Market |
| 02362864 | AVA-CEFPROZIL | AVANSTRA INC | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG | Cancelled Post Market |
| 02324180 | CEFPROZIL | PRO DOC LIMITEE | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG | Cancelled Post Market |
| 02332027 | CEFPROZIL POWDER FOR ORAL SUSPENSION | RANBAXY PHARMACEUTICALS CANADA INC. | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Cancelled Pre Market |
| 02332035 | CEFPROZIL TABLETS | RANBAXY PHARMACEUTICALS CANADA INC. | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Cancelled Pre Market |
| 02332043 | CEFPROZIL TABLETS | RANBAXY PHARMACEUTICALS CANADA INC. | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG | Cancelled Pre Market |
| 02317303 | MINT-CEFPROZIL | MINT PHARMACEUTICALS INC | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Cancelled Post Market |
| 02317311 | MINT-CEFPROZIL | MINT PHARMACEUTICALS INC | Tablet | CEFPROZIL (CEFPROZIL MONOHYDRATE) 500 MG | Cancelled Post Market |
| 02303426 | SANDOZ CEFPROZIL | SANDOZ CANADA INCORPORATED | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 125 MG | Cancelled Post Market |
| 02303434 | SANDOZ CEFPROZIL | SANDOZ CANADA INCORPORATED | Powder For Suspension | CEFPROZIL (CEFPROZIL MONOHYDRATE) 250 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36304 | 2025-10-31 | Supplement to an Abbreviated New Drug Submission (SANDS) | Administrative: Change in product name |
| 22788 | 2019-10-15 | Abbreviated New Drug Submission (ANDS) | MANUFACTURER AND PRODUCT NAME CHANGE |
| 8699 | 2007-04-10 | Abbreviated New Drug Submission (ANDS) |